IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1076-1100 out of 1330.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

Public Release: 3-Apr-2015
Molecular Cell
Study reveals molecular genetic mechanisms driving breast cancer progression
Researchers at UT Southwestern Medical Center have uncovered how the body's inflammatory response can alter how estrogen promotes the growth of breast cancer cells.

Contact: Remekca Owens
remekca.owens@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 3-Apr-2015
TechConnect World Innovation Summit & Expo
ACS Applied Materials & Interfaces
Studies find $1 test using gold nanoparticles outperforms PSA screen for prostate cancer
A test that uses gold nanoparticles to detect early-stage prostate cancer costs less than $1, returns results in minutes and is more accurate than standard PSA screening, pilot studies show. Developed by a researcher at the University of Central Florida's NanoScience Technology Center, the new technique leverages the ability of gold nanoparticles to attract cancer biomarkers.

Contact: Mark Schlueb
mark.schlueb@ucf.edu
407-823-0221
University of Central Florida

Public Release: 2-Apr-2015
Cell Reports
Dual therapy's 1-2 punch knocks out drug-resistant lung cancer
Capitalizing on a rare opportunity to thoroughly analyze a tumor from a lung cancer patient who had developed resistance to targeted drug treatment, UC San Francisco scientists identified a biological escape hatch that explains the resistance, and developed a strategy in mice for shutting it down.
Bonnie J. Addario Lung Cancer Foundation, National Institutes of Health, Howard Hughes Medical Institute, Doris Duke Charitable Foundation, American Lung Association, Sidney Kimmel Foundation for Cancer Research, Searle Scholars Program, and others

Contact: Pete Farley
peter.farley@ucsf.edu
415-502-6397
University of California - San Francisco

Public Release: 2-Apr-2015
Cancer Cell
Body's cancer defenses hijacked to make pancreatic and lung cancers more aggressive
Cancer Research UK scientists have discovered that a vital self-destruct switch in cells is hijacked -- making some pancreatic and non small cell lung cancers more aggressive, according to research published in Cancer Cell today.

Contact: Emily Head
emily.head@cancer.org.uk
020-346-96189
Cancer Research UK

Public Release: 2-Apr-2015
JAMA Oncology
Potential chemoresistance after consuming fatty acid in fish, fish oil
Researchers found that consuming the fish herring and mackerel, as well as three kinds of fish oils, raised blood levels of the fatty acid 16:4(n-3), which experiments in mice suggest may induce resistance to chemotherapy used to treat cancer, according to a study published online by JAMA Oncology.

Contact: Emile E. Voest
e.voest@nki.nl
The JAMA Network Journals

Public Release: 2-Apr-2015
Science
Personalized melanoma vaccines marshal powerful immune response
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. The research is reported April 2 in Science Express, in a special issue devoted to cancer immunology and immunotherapy.
Barnes-Jewish Hospital Foundation, Siteman Cancer Frontier Fund, Our Mark on Melanoma Foundation, Come Out Swinging Foundation, Blackout Melanoma Foundation, NIH/National Cancer Institute

Contact: Jim Goodwin
jgoodwin@wustl.edu
314-286-0166
Washington University School of Medicine

Public Release: 2-Apr-2015
Cell
An 'evolutionary relic' of the genome causes cancer
Pseudogenes have long been considered 'genomic junk,' mysterious remnants of evolution. Now, a scientific team in the Cancer Research Institute at Beth Israel Deaconess Medical Center has found that one of these evolutionary relics caused the development of an aggressive cancer in an animal model -- suggesting the need to sequence this vast genomic 'dark matter' in pursuit of precision cancer therapies.
National Institutes of Health, DOD Prostate Cancer Research Program, American Cancer Society, Cancer Research UK, Wellcome Trust, International Assn. for Cancer Research, Italian Assn. for Cancer Research, German Academy of Sciences Leopoldina

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center

Public Release: 2-Apr-2015
Nature Communications
Key mechanism identified in tumor-cell proliferation in pediatric bone cancers
A particular molecular pathway permits stem cells in pediatric bone cancers to grow rapidly and aggressively, according to researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center.

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Public Release: 2-Apr-2015
Cancer Letters
Nanoparticles may exploit tumor weaknesses to selectively attack cancers
Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer. The approach may represent a new fourth arm of targeted pediatric cancer treatment, joining T-cell immunotherapy, radioactive isotopes and kinase inhibitors that disrupt cancer-driving signaling.
National Institutes of Health, Alex's Lemonade Stand Foundation, V Foundation

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia

Public Release: 2-Apr-2015
Journal of Thoracic Oncology
Physical activity benefits lung cancer patients and survivors
Exercise and physical activity should be considered as therapeutic options for lung cancer as they have been shown to reduce symptoms, increase exercise tolerance, improve quality of life, and potentially reduce length of hospital stay and complications following surgery for lung cancer.

Contact: Murry Wynes
Murry.Wynes@iaslc.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 2-Apr-2015
Journal of the National Cancer Institute
Mayo Clinic researchers combine common genetic variants to improve breast cancer
Recent large-scale genomic analyses have uncovered dozens of common genetic variants that are associated with breast cancer. Each variant, however, contributes only a tiny amount to a person's overall risk of developing the disease.
NIH/National Cancer Institute, Breast Cancer Research Foundation

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 2-Apr-2015
Science
Strong grasp of immune response dynamics will enhance checkpoint blockade
Spreading the success of cancer immunotherapy beyond those patients currently enjoying powerful, long-term responses to treatment requires greater understanding of the immune response to tumors, two leaders in the field note in a review in the April 3 Science.

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center

Public Release: 2-Apr-2015
Molecular Cell
USC Norris study finds herpesvirus activates RIG-I receptor to evade body's immune system
Using herpesvirus, molecular immunologists from the University of Southern California Norris Comprehensive Cancer Center have discovered a cellular process that activates a critical immune defense against pathogens, which could have implications for developing drugs to bolster one's immunity to infection. Some herpesvirus infections lead to cancer.
National Institutes of Health, American Cancer Society, USC Norris Comprehensive Cancer Center

Contact: Alison Trinidad
alison.trinidad@usc.edu
323-442-3941
University of Southern California - Health Sciences

Public Release: 2-Apr-2015
Genes & Development
Cancer genes turned off in deadly brain cancer
Scientists have identified a small RNA molecule that can suppress cancer-causing genes in mice with glioblastoma mulitforme, a deadly and incurable type of brain tumor. While standard chemotherapy drugs damage DNA to stop cancer cells from reproducing, the new method stops the source that creates those cancer cells. The approach could also potentially be used for gene silencing in other cancers and diseases of genetic origin.
National Institutes of Health

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University

Public Release: 2-Apr-2015
Journal of Biological Chemistry
Small RNA plays big role suppressing cancer
Researchers at UC Davis have unraveled some of these relationships, identifying several interactions that directly impact liver and colon cancer.
National Institutes of Health

Contact: Dorsey Griffith
dgriffith@ucdavis.edu
916-734-9118
University of California - Davis Health System

Public Release: 2-Apr-2015
Palliative Medicine
Dying patients' choices not always aligned to caregivers'
An illuminating study compares the willingness of stage IV cancer patients, and their caregivers; to pay to extend their lives by one year against that of other end-of-life improvements. The research, led by members of the Lien Centre for Palliative Care and collaborators from the National Cancer Centre Singapore, was recently published in the journal, Palliative Medicine.
Lien Centre for Palliative Care

Contact: Dharshini Subbiah
dharshini.subbiah@duke-nus.edu.sg
659-616-7532
Duke-NUS Graduate Medical School Singapore

Public Release: 2-Apr-2015
Science Translational Medicine
NTU finds new treatment options for colon cancer
Scientists from Nanyang Technological University and Sweden's Karolinska Institutet have discovered that an existing chemotherapy drug used to treat leukemia could prevent and control the growth of colorectal tumors.
Nanyang Technological University's Lee Kong Chian School of Medicine, Singapore Millennium Foundation, National Cancer Centre Singapore, Swedish Research Council, Swedish Cancer Society, Karolinska Institutet, Tobias Foundation, and others

Contact: Lester Kok
lesterkok@ntu.edu.sg
Nanyang Technological University

Public Release: 1-Apr-2015
PLOS Pathogens
Anticancer drug can spur immune system to fight infection
Imatinib, an example of a 'targeted therapy' against cancer, or related drugs might be tools to fight a variety of infections.
NIH/National Institute of Allergy and Infectious Diseases, NIH/National Heart, Lung, and Blood Institute

Contact: Quinn Eastman
qeastma@emory.edu
404-727-7829
Emory Health Sciences

Public Release: 1-Apr-2015
Genes & Development
A CNIO team succeeds in doubling the life span of mice suffering from premature aging
An increase in the capacity to produce nucleotides, the 'building blocks' of DNA, reduces genome fragility and counteracts premature aging in mutant mice for the ATR protein. The experiments may explain the beneficial effects of folic acid, a precursor of nucleotides, which are clinically used to alleviate the degenerative symptoms associated with aging.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 1-Apr-2015
Nature
Scientists drill down to genetic root of prostate tumor development
Scientists have revealed the root of prostate cancers in individual men, discovering that despite huge genetic variety between tumors they also share common gene faults -- insight that could offer new treatment hopes.

Contact: Emily Head
emily.head@cancer.org.uk
020-346-96189
Cancer Research UK

Public Release: 1-Apr-2015
BMC Veterinary Research
Old cancer drug could have new use in fighting cancer
Jeffrey Bryan, an associate professor of oncology at the MU College of Veterinary Medicine, found that an old cancer drug can not only kill cancer cells, but also works to change how certain cancer cells function, weakening those cells so they can be killed by other drugs.

Contact: Nathan Hurst
hurstn@missouri.edu
573-882-6217
University of Missouri-Columbia

Public Release: 1-Apr-2015
Science Translational Medicine
Cancer's relentless evolution
In new research, Carlo Maley, Ph.D., and his colleagues describe compulsive evolution and dramatic genetic diversity in cells belonging to one of the most treatment-resistant and lethal forms of blood cancer: acute myeloid leukemia (AML). The authors suggest the research may point to new paradigms in both the diagnosis and treatment of aggressive cancers, like AML.

Contact: joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University

Public Release: 1-Apr-2015
Science
Locking up an oncogenic transcription
A novel molecule designed by scientists at the University of Massachusetts Medical School and the University of Virginia inhibits progression of a hard-to-treat form of recurring acute myeloid leukemia in patient tissue. The small molecule is one of the first designed to specifically target a cancer-causing transcription factor.

Contact: Jim Fessenden
james.fessenden@umassmed.edu
508-856-2688
University of Massachusetts Medical School

Public Release: 1-Apr-2015
Nature
Study affirms lethal prostate cancer can spread from other metastatic sites
A new genomic analysis of tissue from patients with prostate cancer has added more evidence that cells within metastases from such tumors can migrate to other body parts and form new sites of spread on their own.
Cancer Research UK, Academy of Finland, Cancer Society of Finland, PELICAN Autopsy Study, Johns Hopkins Brady Urological Institute, John and Kathe Dyson, NIH/National Cancer Institute

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 1-Apr-2015
BMJ Open
Older people at higher risk of emergency cancer diagnosis
People over 60 are at higher risk of being diagnosed with lung or bowel cancer as an emergency in hospital than younger people, according to a Cancer Research UK-supported report, published today by BMJ Open.
Part-funded by Cancer Research UK

Contact: Liz Smith
liz.smith@cancer.org.uk
020-346-98300
Cancer Research UK

Showing releases 1076-1100 out of 1330.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

  Search News Releases

     

 

EurekAlert!